AIC
CVKD icon

Archer Investment Corporation’s Cadrenal Therapeutics CVKD Stock Holding History

Archer Investment Corporation’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117 Hold
35
– – ﹤0.01% 1179
2026
Q1 		$179 Hold
35
– – ﹤0.01% 1179
2025
Q4 		$237 Hold
35
– – ﹤0.01% 1113
2025
Q3 		$484 Hold
35
– – ﹤0.01% 1111
2025
Q2 		$422 Hold
35
– – ﹤0.01% 1088
2025
Q1 		$617 Hold
35
– – ﹤0.01% 1032
2024
Q4 		$507 Buy
+35
New +$506 ﹤0.01% 1039

Other funds holding CVKD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Archer Investment Corporation's CVKD Position: Q2 2026 in Review

Archer Investment Corporation held its Cadrenal Therapeutics (CVKD) position steady in Q2 2026 at 35 shares worth $117. The position accounts for ﹤0.01% of the portfolio, ranked #1179.

Archer Investment Corporation first reported a position in CVKD in Q4 2024 and has held it in 7 quarters since. The position peaked at $617 in Q1 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q2 2026.

  • Archer Investment Corporation held 35 shares of Cadrenal Therapeutics worth $117 as of Q2 2026.
  • Archer Investment Corporation left its Cadrenal Therapeutics share count unchanged in Q2 2026.
  • Cadrenal Therapeutics made up ﹤0.01% of Archer Investment Corporation's portfolio in Q2 2026, its #1179 holding.
  • Archer Investment Corporation first reported a position in Cadrenal Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Archer Investment Corporation's Cadrenal Therapeutics position peaked at $617 in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2026.

Based on Archer Investment Corporation's 13F filing for Q2 2026, filed 3 Aug 2026.